Health Care [ 10/12 ] | Biotechnology [ 39/73 ]
NASDAQ | Common Stock
XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat gout and progressive kidney disease.
Its drug development programs include XRx-026, which is in the third phase for the treatment of gout; XRx-008, which is in the second phase to treat autosomal dominant polycystic kidney disease; XRx-101, which is in the second phase to treat acute kidney injury associated with respiratory virus infection; and XRX-225, which is in the preclinical stage for the treatment of type 2 diabetic nephropathy.
It has a license agreement with the University of Florida Research Foundation, Inc. for the use of uric acid lowering agent to treat insulin resistance.
The company is based in Calgary, Canada.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 15, 25 | -0.19 Decreased by -424.23% | - |
| May 14, 25 | 0.04 Decreased by -97.04% | - |
| Mar 25, 25 | -0.81 Decreased by -27.36% | -0.41 Decreased by -97.56% |
| Nov 12, 24 | -0.20 Increased by +69.82% | - |
| Aug 14, 24 | 0.06 Increased by +107.33% | -0.92 Increased by +106.35% |
| May 15, 24 | 1.35 Increased by +1.33 K% | -0.28 Increased by +588.04% |
| Dec 31, 23 | -0.64 Decreased by -218.00% | -0.81 Increased by +21.96% |
| Nov 14, 23 | -0.67 Decreased by -292.27% | -0.19 Decreased by -252.63% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 25 | 0.00 Decreased by N/A% | -717.70 K Decreased by -522.01% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 25 | 0.00 Decreased by N/A% | -698.67 K Increased by +76.86% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 24 | 0.00 Decreased by N/A% | 119.08 K Decreased by -95.59% | Increased by +N/A% Decreased by N/A% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -587.01 K Increased by +55.98% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | 170.07 K Increased by +110.05% | Increased by +N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -3.02 M Decreased by -64.79% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 0.00 Decreased by N/A% | 2.70 M Increased by +192.50% | Increased by +N/A% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -1.33 M Increased by +14.66% | Decreased by N/A% Decreased by N/A% |